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Abstract
Indications for transcatheter valve implantation have been extended to treat native valve aortic regurgitation in case of disproportionate
risk for open surgery. Transcatheter aortic valves are also an attractive alternative in patients who refuse blood transfusions. We report the
successful off-label implantation of a self-expandable transcatheter valve in a Jehovah’s Witness with prior replacement of the ascending
aorta for Type A dissection, residual severe aortic regurgitation and refractory heart failure.
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INTRODUCTION
Indications for transcatheter aortic valve implantation (TAVI)
device have been extended to treat pure native valve aortic regur-
gitation (AR) in patients judged at high or extreme risk for open
heart surgery [1, 2]. Off-label indications for TAVI in AR also
include patients with a history of Type A aortic dissection repair.
In parallel, TAVI represents an attractive alternative in patients who
refuse blood transfusions, and has been anecdotally reported in
Jehovah’s Witnesses ( JWs) with aortic stenosis [3, 4]. We report the
successful transcatheter implantation of a self-expandable valve to
treat AR in a JW with previous graft replacement of the supracor-
onary ascending aorta for acute dissection.
CASE REPORT
A 78-year old female JW with hypertension, dyslipidaemia and
obesity had undergone emergency Type A acute aortic dissection
repair 4 years earlier. The previous life-saving operation consisted
of culprit replacement of the supracoronary ascending aorta with
a short 30-mm dacron graft, employing standard cardioplegia
with aortic cross-clamping, but avoiding hypothermic circulatory
arrest to minimize the risks of severe anaemia. The aortic root had
been preserved and valve commissures resuspended. The patient
survived without transfusions and recovered free of complications.
Four years thereafter, however, she presented with severe AR and
refractory heart failure, with two hospitalizations in 4 months. The
risk of an open reoperation to replace the aortic valve without
written consent for blood transfusion was judged prohibitive, and
TAVI with a CoreValve® (Medtronic, Inc., Minneapolis, MN, USA)
was considered by the heart team.
Angiography and computed tomography outlined normal cor-
onary arteries and the absence of aortic calcifications (Fig. 1). The
aortic annular diameter measured 26 mm, whereas the arch and
thoracoabdominal aorta were near normal. Preprocedural 3D
virtual valve simulation was undertaken with Osirix post-processing
software (Pixmeo, Geneva, Switzerland) to determine optimal sizing
for adequate sealing in the aortic annulus and prosthetic supracor-
onary aorta, taking into account the inflow and outflow diameters
and radial forces of the CoreValve’s frame. Ultimately, a 29-mm
valve with 20% oversizing was chosen for implantation, targeting
the device’s proximal end 6 mm below the annular plane to minim-
ize valve embolization hazards (Fig. 2, Video 1). The procedure was
carried out under general anaesthesia with surgical cut-down of the
left common femoral artery, avoiding the previously cannulated
right femoral artery to minimize bleeding hazards. No conduction
disturbance occurred despite a slightly caudal implantation. The
following course was uneventful and the patient was discharged on
postoperative day 6. At 18-months follow-up, the patient is in
New York Heart Association functional class I with normal
CoreValve function at echocardiography.
DISCUSSION
Surgical valve replacement represents the standard of care for the
treatment of severe aortic valve disease. TAVI has become a thera-
peutic option for patients with calcific aortic valve stenosis judged
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Figure 1: 3D computed tomographic angiography. (A) Mild tortuousity of the aorta and supra-aortic trunks, and absence of aortic calcifications proximal to the left
subclavian artery origin. (B) Partial dissection of the distal ascending aorta. (C) Residual chronic aortic root dissection. (D) Absence of left main coronary artery
obstruction.
Figure 2: Aortograms. (A) No migration after release of the proximal two-thirds of the CoreValve, despite severe aortic regurgitation and no annular calcifications.
Initial deployment of the device was conducted during rapid ventricular pacing to reduce pulse pressure. (B) Correct positioning with trivial residual paravalvular leak
after valve implantation.
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at too high a risk for open heart surgery. Although generally
considered off-label in view of the lack of aortic annular calcium,
which renders valve deployment more insecure, non-conventional
TAVI has also been performed in smaller series of patients consid-
ered inoperable with native valve AR. The latter include patients
with prior Type A aortic dissection repair [1, 2], with a left ventricu-
lar assist device or prior heart transplantation, homograft or Ross
operation failure, healed endocarditis and bicuspid valves. More
often, however, TAVI for AR has been indicated as a valve-in-valve
procedure in structural bioprosthetic valve deterioration.
Balloon-expandable transcatheter valves are generally consid-
ered less suitable for TAVI in native valve AR in view of their lack
of intrinsic radial force and the consequent difficulties in anchor-
ing the device at the annular level with little or no calcium [2]. In
fact, despite the use of devices based on nitinol self-expanding
technology, including the CoreValve and the newer generation
Jenavalve ( Jenavalve Technology, Inc., Munich, Germany) [5],
supra-annular migration and requirement for implantation of a
second valve during the procedure have been described mostly in
patients with AR and no documented calcification [1]. The
Jenavalve is the only valve approved for AR treatment, but requires
a transapical access, which was considered at higher risk for
bleeding. Importantly, the acute dissection in this particular case
was limited to the ascending aorta and arch and the descending
aorta was not involved. Consequently, the transfemoral approach
was suitable for the procedure.
In parallel, TAVI has also been anecdotally reported to treat
aortic stenosis in JWs [3, 4], thus avoiding the hazards of severe
anaemia related to open heart surgery. This is an attractive ap-
proach, particularly in case of comorbidities or predicted tech-
nical challenges, such as redo surgery. In the case described, the
risk of a conventional on-pump reoperation was considered dis-
proportionate without the availability of blood products, and
cannot be correctly predicted by the EuroSCORE II or the Society
of Thoracic Surgeons risk models, which returned an estimated
operative mortality risk of 6.54 and 6.27%, respectively.
In conclusion, this case highlights the potential for extended
indications for TAVI with a self-expandable device in patients with
non-calcific aortic valve disease, particularly when multiple risk
factors for a conventional valve replacement operation coexist.
Severe AR in a JW with a history of emergency ascending aortic
surgical repair for acute dissection is a clear example of a challen-
ging case, for which off-label TAVI may well represent the most
promising option.
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Video 1: Aortography. In sequence, baseline severe aortic regurgitation with no
annular calcifications, initial deployment of the CoreValve during rapid ven-
tricular pacing, no migration after release of the proximal two-thirds of the
device, and correct positioning with trivial residual paravalvular leak after valve
implantation.
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